European Companies Search Engine
EU funding (€6,004,153): Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain Hor1 Jan 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain
We propose a clinical program for the evaluation of a novel bone-regeneration product OSTEOproSPINE as a treatment for intractable chronic back pain. OSTEOproSPINE is a novel bone regeneration therapy composed of OSTEOGROW (recombinant human bone morphogenetic protein 6 [rhBMP6] delivered in autologous peripheral blood coagulum) reinforced with allograft (a compression resistant matrix). OSTEOproSPINE is designed to guide the formation of new bone at extra-skeletal site and replace autograft harvested from patient’s iliac crest for the fusion of lumbar vertebrae. By generating new bone, OSTEOproSPINE will restore the spine’s weight bearing function, reduce the severity of back pain and improve the success rate of posterolateral spinal fusion surgery. The program consortium of 12 partners from 5 EU member states has been assembled to conduct a Phase II, randomized, patient- and evaluator-blinded clinical trial of OSTEOproSPINE. Four clinical centers will enroll 143 patients suffering from degenerative disc disease to assess OSTEOproSPINE efficacy and safety in comparison with Standard of care (autograft) and Osteogrow. The Ethics Committee of the leading clinical site in Vienna has already granted a conditional approval for this trial. As the coordinating institution of the FP7 HEALTH project Osteogrow (Grant No. 279239), we have evaluated Osteogrow in Phase I/II clinical trials for distal radius fracture and high tibial osteotomy. Osteogrow exhibited excellent safety profile in these trials, supporting OSTEOproSPINE safety for administration in humans. A positive outcome of proposed trial will confirm OSTEOproSPINE potential to form a functioning new bone in human and by this restore the spine’s function and improve the quality of life in patients with degenerative disc disorders using the ground principle of regenerative medicine: “provide the correct molecular signals to a population of presumptive cells in a permissive microenvironment”.
Funded Companies:
| Company name | Funding amount |
| 2KMM sp. z o.o. | €377,250 |
| Clinres Farmacija Raziskave d.o.o. | €705,763 |
| Eurice European Research AND Project Office GmbH | €445,000 |
| Genera Istrazivanja d.o.o. | €1,138,750 |
| Kepler Universitatsklinikum GmbH | €0.00 |
| Medizinische Universitaet Wien | €950,207 |
| Medizinische Universitat Graz | €322,042 |
| Opca Bolnica Varazdin | €0.00 |
| Paul Regulatory Services Ltd. | €14,154.00 |
| Qbex GmbH | €275,346 |
| Smart-Medico d.o.o. | €253,533 |
| Sveuciliste U Zagrebu Medicinski Fakultet | €720,125 |
| Triadelta Partneri d.o.o. | €183,108 |
| Universitat Linz | €382,626 |
| University OF Zagreb-Faculty OF Veterinary Medicine | €236,250 |
Source: https://cordis.europa.eu/project/id/779340
The filing refers to a past date, and does not necessarily reflect the current state.